SG11201901063SA - Therapeutic agents for neurodegenerative diseases - Google Patents

Therapeutic agents for neurodegenerative diseases

Info

Publication number
SG11201901063SA
SG11201901063SA SG11201901063SA SG11201901063SA SG11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA
Authority
SG
Singapore
Prior art keywords
international
begbroke
pct
neurodegenerative diseases
english
Prior art date
Application number
SG11201901063SA
Other languages
English (en)
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201901063S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613829.9A external-priority patent/GB201613829D0/en
Priority claimed from GBGB1702551.1A external-priority patent/GB201702551D0/en
Priority claimed from GBGB1705766.2A external-priority patent/GB201705766D0/en
Priority claimed from GBGB1706867.7A external-priority patent/GB201706867D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of SG11201901063SA publication Critical patent/SG11201901063SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201901063SA 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases SG11201901063SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1613829.9A GB201613829D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1702551.1A GB201702551D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1705766.2A GB201705766D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1706867.7A GB201706867D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
PCT/IB2017/054929 WO2018029658A1 (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
SG11201901063SA true SG11201901063SA (en) 2019-03-28

Family

ID=59859424

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901063SA SG11201901063SA (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases

Country Status (29)

Country Link
US (3) US12144792B2 (enExample)
EP (3) EP4467195A3 (enExample)
JP (3) JP6957602B2 (enExample)
KR (4) KR102413756B1 (enExample)
CN (4) CN109789114A (enExample)
AU (3) AU2017308865B2 (enExample)
BR (1) BR112019002730A2 (enExample)
CA (1) CA3033564A1 (enExample)
CY (1) CY1121930T1 (enExample)
DK (1) DK3416631T3 (enExample)
ES (1) ES2733677T3 (enExample)
HR (1) HRP20191055T1 (enExample)
HU (1) HUE045043T2 (enExample)
IL (3) IL264641B2 (enExample)
LT (1) LT3416631T (enExample)
MA (2) MA43828B1 (enExample)
MD (1) MD3416631T2 (enExample)
ME (1) ME03454B (enExample)
MX (3) MX383499B (enExample)
NZ (2) NZ750421A (enExample)
PL (1) PL3416631T3 (enExample)
PT (1) PT3416631T (enExample)
RS (1) RS59048B1 (enExample)
RU (1) RU2756519C2 (enExample)
SG (1) SG11201901063SA (enExample)
SI (1) SI3416631T1 (enExample)
SM (1) SMT201900370T1 (enExample)
TN (1) TN2019000033A1 (enExample)
WO (1) WO2018029658A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10219815B2 (en) 2005-09-22 2019-03-05 The Regents Of The University Of Michigan Histotripsy for thrombolysis
WO2016210133A1 (en) 2015-06-24 2016-12-29 The Regents Of The Universtiy Of Michigan Histotripsy therapy systems and methods for the treatment of brain tissue
KR102467953B1 (ko) 2016-08-11 2022-11-16 인트라바이오 리미티드 리소좀 축적 질환과 관련된 약제 조성물 및 용도
MA43828B1 (fr) 2016-08-11 2019-09-30 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
SG11202003390UA (en) * 2017-10-18 2020-05-28 Intrabio Ltd Therapeutic agents for neurodegenerative diseases
CA3091353A1 (en) * 2018-02-15 2019-08-22 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
CA3120586A1 (en) 2018-11-28 2020-06-04 Histosonics, Inc. Histotripsy systems and methods
BR112021010923A2 (pt) * 2018-12-06 2021-08-24 Intrabio Ltd Análogos deuterados de acetileucina
KR20250171484A (ko) * 2019-03-02 2025-12-08 인트라바이오 리미티드 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체
JP7432711B2 (ja) * 2019-09-17 2024-02-16 エフ． ホフマン－ラ ロシュ アーゲー 動作障害患者に対する個別化医療の改善
WO2021144720A1 (en) * 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
KR20230015433A (ko) * 2020-05-22 2023-01-31 인트라바이오 리미티드 운동실조를 치료하기 위한 아세틸 류신과 4-아미노피리딘 또는 아세타졸아미드의 조합물
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
WO2024092272A1 (en) 2022-10-28 2024-05-02 Histosonics, Inc. Histotripsy systems and methods
KR20260003742A (ko) 2023-04-20 2026-01-07 히스토소닉스, 인크. 치료 계획 및 요법을 위한 사용자 인터페이스들 및 작업 흐름들을 포함하는 히스토트립시 시스템들 및 연관된 방법들
WO2025151578A1 (en) * 2024-01-12 2025-07-17 Intrabio Inc. N-acetyl-leucine for use in the treatment of prodromal alpha-synucleinopathies
WO2025163129A1 (en) * 2024-02-01 2025-08-07 Intrabio Ltd. Acetyl-leucine for treating parkinson´s disease
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
EP2946779A1 (en) 2007-02-22 2015-11-25 Beiersdorf AG Cosmetic and pharmaceutical applications of n-acetylhydroxyproline
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CA2928701A1 (en) * 2013-10-28 2015-05-07 Naurex, Inc. Nmda receptor modulators and prodrugs, salts, and uses thereof
WO2017182802A1 (en) 2016-04-19 2017-10-26 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
MA43828B1 (fr) 2016-08-11 2019-09-30 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives

Also Published As

Publication number Publication date
PL3416631T3 (pl) 2019-11-29
SMT201900370T1 (it) 2019-09-09
RS59048B1 (sr) 2019-08-30
RU2019106506A (ru) 2020-09-17
WO2018029658A1 (en) 2018-02-15
CN121081445A (zh) 2025-12-09
EP4467195A2 (en) 2024-11-27
DK3416631T3 (da) 2019-07-15
CY1121930T1 (el) 2020-10-14
MA43828A (fr) 2018-12-26
MA47521A (fr) 2021-04-21
MX2024004439A (es) 2025-11-03
CA3033564A1 (en) 2018-02-15
EP4467195A3 (en) 2025-03-19
AU2025202077B2 (en) 2026-04-30
MD3416631T2 (ro) 2019-09-30
TN2019000033A1 (fr) 2020-07-15
IL264641B2 (en) 2024-07-01
JP2022003085A (ja) 2022-01-11
US20230210799A1 (en) 2023-07-06
AU2023202121A1 (en) 2023-05-04
MA43828B1 (fr) 2019-09-30
EP3416631B1 (en) 2019-05-15
JP6957602B2 (ja) 2021-11-02
JP7833272B2 (ja) 2026-03-19
ME03454B (me) 2020-01-20
US12144792B2 (en) 2024-11-19
JP2019524822A (ja) 2019-09-05
AU2025202077A1 (en) 2025-04-10
AU2023202121B2 (en) 2025-01-23
KR102785448B1 (ko) 2025-03-21
PT3416631T (pt) 2019-07-11
MX2021006901A (es) 2021-07-07
KR20240068761A (ko) 2024-05-17
ES2733677T3 (es) 2019-12-02
NZ790893A (en) 2026-03-27
AU2017308865A1 (en) 2019-02-21
MX2019001575A (es) 2019-08-01
RU2021128045A (ru) 2021-11-16
EP3416631A1 (en) 2018-12-26
SI3416631T1 (sl) 2019-09-30
CN116492328A (zh) 2023-07-28
AU2017308865B2 (en) 2023-04-13
IL264641B1 (en) 2024-03-01
JP2023175762A (ja) 2023-12-12
US20200179320A1 (en) 2020-06-11
IL310799A (en) 2024-04-01
KR102413756B1 (ko) 2022-06-27
MX383499B (es) 2025-03-14
HUE045043T2 (hu) 2019-12-30
CN109789114A (zh) 2019-05-21
IL264641A (en) 2019-04-30
CN116459244A (zh) 2023-07-21
US20240189267A1 (en) 2024-06-13
EP3583940A1 (en) 2019-12-25
RU2019106506A3 (enExample) 2020-10-29
RU2756519C2 (ru) 2021-10-01
KR20220093385A (ko) 2022-07-05
KR20190039227A (ko) 2019-04-10
KR20250042197A (ko) 2025-03-26
BR112019002730A2 (pt) 2019-05-14
HRP20191055T1 (hr) 2019-09-06
LT3416631T (lt) 2019-08-26
NZ750421A (en) 2026-03-27
IL310801A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201907034PA (en) Methods of treating influenza
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201811559WA (en) Cancer treatment combinations
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201908159QA (en) Dual magl and faah inhibitors
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201808221QA (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201901249YA (en) Aza-indazole compounds for use in tendon and/or ligament injuries
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901925RA (en) Methods of treating acute kidney injury